Alveolar Macrophage Proteomics in HIV-associated Emphysema (HIVE)
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Alveolar Macrophage Proteomics in HIV-associated Emphysema|
- examine the natural history of smoking related lung damage in patients with HIV [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]HIV-Seropositive individuals are at increased risk of developing pulmonary emphysema (1,2). With improved therapy for HIV, and increased life expectancy in this population with a high smoking prevalence, chronic obstructive pulmonary disease (COPD) may assume an increasingly important role with respect to health related quality of life and medical complications. This research will provide a unique opportunity to examine the natural history of smoking related lung damage in patients with HIV infection. In addition, this research will involve sampling of lung cells to determine if there are unique proteins present that may be related to the increased risk of emphysema in this population. This may shed important insight into how the lung responds to injury and how it repairs itself. If critical proteins can be identified, treatment strategies may eventually be developed to either decrease proteins causing injury or increase protective proteins.
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2006|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
HIV smokers with emphysema
HIV smokers without emphysema
To delineate the natural history of HIV associated emphysema in the HAART era. To compare the alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00823927
|United States, Ohio|
|The Ohio State University|
|Columbus, Ohio, United States, 43026|
|Principal Investigator:||Philip T Diaz, MD||Ohio State University|